subscribeSubscribe
Takeda`s Iclusig wins first-line FDA nod to treat Ph+ALL

Takeda`s Iclusig wins first-line FDA nod to treat Ph+ALL
FIERCE BIOTECH
20 Mar 2024
Share Share
Takeda Announces U.S. FDA Approval of sNDA) for ICLUSIG® (ponatinib)

Takeda Announces U.S. FDA Approval of sNDA) for ICLUSIG® (ponatinib)
BUSINESSWIRE
19 Mar 2024
Share Share
Ponatinib Plus Low-Dose Chemotherapy Improves MRD– CR Rates in Ph+ ALL

Ponatinib Plus Low-Dose Chemotherapy Improves MRD– CR Rates in Ph+ ALL
ONCLIVE
24 Aug 2023
Share Share
Takeda`s Iclusig tops Novartis` Gleevec decisively in Ph+ALL

Takeda`s Iclusig tops Novartis` Gleevec decisively in Ph+ALL
Kevin Dunleavy FIERCE PHARMA
15 Feb 2023
Share Share
FDA Confirms Paragraph IV Patent Litigation for Ponatinib Hydrochloride

FDA Confirms Paragraph IV Patent Litigation for Ponatinib Hydrochloride

FDA
13 Jan 2023
Share Share
Phase 3 Trial of ICLUSIG Met Primary Endpoint in Diagnosed Ph+ ALL

Phase 3 Trial of ICLUSIG Met Primary Endpoint in Diagnosed Ph+ ALL
BUSINESSWIRE
17 Nov 2022
Share Share
FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant

FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant
CANCERNETWORK
18 Dec 2020
Share Share
FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant

FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant
CANCERNETWORK
18 Dec 2020
Share Share
Marker Reports Interim Results of its MultiTAA-Specific T Cell Therapy

Marker Reports Interim Results of its MultiTAA-Specific T Cell Therapy
PRNEWSWIRE
29 May 2020
Share Share
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program
TAKEDA
29 May 2020
Share Share